Finny Kuruvilla, MD, PhD
Co-Chief Investment Officer, Senior Portfolio Manager, Founding Member
Finny Kuruvilla, MD, PhD serves as co-CIO and Senior Portfolio Manager for Eventide. Dr. Kuruvilla has responsibilities for investments across many Eventide products, including the venture capital line of business.
Dr. Kuruvilla has a background in healthcare, statistics, and investing. Concurrent with his early years at Eventide, he was a Principal at Clarus Ventures, a healthcare and life sciences venture capital firm subsequently acquired by Blackstone. Earlier in his career, Dr. Kuruvilla was a postdoctoral research fellow at the Broad Institute of Harvard and MIT, where he led the development of a new microarray between the Broad Institute and a publicly-traded company Affymetrix. Prior to his investing career, Dr. Kuruvilla was a practicing physician serving in several capacities including as chief resident and fellow at the Brigham and Women’s Hospital and Boston Children’s Hospital.
Within healthcare and life sciences, Dr. Kuruvilla focuses on investments in Oncology, Neurology, Diagnostics, and Medical Devices. Dr. Kuruvilla serves on the board of directors of Beta Bionics and Casma Therapeutics, portfolio companies of certain other Eventide products. Dr. Kuruvilla holds an MD from Harvard Medical School, a PhD in Chemistry and Chemical Biology from Harvard University, a SM in Electrical Engineering and Computer Science from MIT, and a BS in Chemistry from Caltech.